Could a common arthritis drug tame Sjogren's syndrome?

NCT ID NCT04496960

Ongoing Disease control Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing the safety of tofacitinib (Xeljanz), a drug already used for rheumatoid arthritis, in 23 adults with mild-to-moderate Sjogren's syndrome. Participants take the drug or a placebo daily for 168 days. The goal is to see if the drug is safe and tolerable, with a potential to help control this autoimmune disease that causes dry eyes and mouth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tofacitinib (Xeljanz)
What this could lead to: If this trial shows tofacitinib is safe, it could point toward a new treatment option to help control Sjogren's syndrome symptoms.
What could go wrong: This is a very early, small study with only 23 people. It focuses on safety, not yet on how well the drug works. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation Sjogren syndrome Xerostomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJOGREN'S SYNDROME

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.